Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | CD74 | P04233 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22314911 | 0.89 | SCN5A (0.52) | METTSPOSCN1ASCN4AKCNH2 | |
| SCHEMBL22314557 | 0.79 | SCN5A (0.46) | METTSPOSCN1ASCN4AKCNH2 | |
| SCHEMBL25865133 | 0.78 | TNIK (0.43) | TSPOSCN1ASCN4AKCNH2SCN5A | |
| SCHEMBL22314913 | 0.75 | SCN5A (0.48) | SCN1ASCN4AKCNH2SCN5ASCN9A | |
| SCHEMBL22314528 | 0.73 | GRIN1 (0.42) | SCN1ASCN4AKCNH2SCN5ASCN9A | |
| SCHEMBL22315048 | 0.73 | TNIK (0.43) | TSPOSCN1ASCN4AKCNH2SCN5A | |
| SCHEMBL22314564 | 0.71 | TNIK (0.48) | CD74MIF | |
| SCHEMBL25869117 | 0.70 | TSPO (0.52) | TSPO | |
| SCHEMBL25868217 | 0.70 | MAPT (0.46) | TSPO | |
| SCHEMBL22314889 | 0.70 | TSPO (0.46) | TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | MET 3724/4885TSPO 394/4885SCN1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.